Our results also show that two dipeptidyl peptidase-4 inhibitors (DPP4) considered as second-line treatments were used more frequently, in combination with metformin, probably to induce a greater weight reduction without intense hypoglycemia [26,27]. This evidence concerns the gene DPP4 and Hypoglycemia.